Corrigendum: Blood pressure targets in the treatment of high blood pressure: A reappraisal of the J-shaped phenomenon (Journal of Human Hypertension (2014) 28 (80-84) DOI: 10.1038/jhh.2013.78);Blood pressure targets in the treatment of high blood pressure: A reappraisal of the J-shaped phenomenon

Journal of Human Hypertension

Volumn 28, Issue 2, 2014, Pages 80-84

  Fuchs, F D ^a   Fuchs, S C ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Blood pressure treatment; J shaped phenomenon

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; INDAPAMIDE PLUS PERINDOPRIL; PERINDOPRIL; PLACEBO; RAMIPRIL; TRANDOLAPRIL PLUS VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DRUG TARGETING; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; HYPOTENSION; J SHAPED PHENOMENON; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; SYSTOLIC BLOOD PRESSURE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERTENSION; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84891850844     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2013.110     Document Type: Erratum

References (43)

1. Anderson TW. Re-examination of some of the Framingham blood pressure data. Lancet 1978; 2: 1139-1141.
2. Stewart IM. Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension. Lancet 1979; 1: 861-865.
3. Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet 1987; 1: 581-584.
4. Farnett L, Mulrow CD, Linn WD, Lucey CR, Tuley MR. The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous? JAMA 1991; 265: 489-495.
5. Lindblad U, Rastam L, Ryden L, Ranstam J, Isacsson SO, Berglund G. Control of blood pressure and risk of first acute myocardial infarction: Skaraborg hypertension project. BMJ 1994; 308: 681-686.
6. Owens P, O'Brien E. Hypotension in patients with coronary disease: can profound hypotensive events cause myocardial ischaemic events? Heart 1999; 82: 477-481.
7. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-1762.
8. Cruickshank JM. Antihypertensive treatment and the J-curve. Cardiovasc Drugs Ther 2000; 14: 373-379.
9. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003; 289: 2560-2571.
10. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M et al. 2013 ESH/ ESC Guidelines for the management of arterial hypertension. Journal of Hypertension 2013; 31: 1281-1357.
11. ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff Jr DC, Grimm Jr RH, Cutler JA et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1575-1585.
12. Chobanian AV. Mixed messages on blood pressure goals. Hypertension 2011; 57: 1039-1040.
13. Mizuno R, Fujimoto S, Saito Y, Okamoto Y. Optimal antihypertensive level for improvement of coronary microvascular dysfunction: the lower, the better? Hypertension 2012; 60: 326-332.
14. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913.
15. Fuchs FD, Fuchs SC, Moreira LB, Gus M. Proof of concept in cardiovascular risk: the paradoxical findings in blood pressure and lipid abnormalities. Vasc Health Risk Manag 2012; 8: 437-442.
16. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: B1665.
17. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887-1898.
18. Langer RD, Ganiats TG, Barrett-Connor E. Paradoxical survival of elderly men with high blood pressure. BMJ 1989; 298: 1356-1358.
19. Okumiya K, Matsubayashi K, Wada T, Fujisawa M, Osaki Y, Doi Y et al. A U-shaped association between home systolic blood pressure and four-year mortality in community-dwelling older men. J Am Geriatr Soc 1999; 47: 1415-1421.
20. Werle MH, Moriguchi E, Fuchs SC, Bruscato NM, de Carli W, Fuchs FD. Risk factors for cardiovascular disease in the very elderly: results of a cohort study in a city in southern Brazil. Eur J Cardiovasc Prev Rehabil 2011; 18: 369-377.
21. Glynn RJ, L'Italien GJ, Sesso HD, Jackson EA, Buring JE. Development of predictive models for long-term cardiovascular risk associated with systolic and diastolic blood pressure. Hypertension 2002; 39: 105-110.
22. Psaty BM, Furberg CD, Kuller LH, Cushman M, Savage PJ, Levine D et al. Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the cardiovascular health study. Arch Intern Med 2001; 161: 1183-1192.
23. van Bemmel T, Holman ER, Gussekloo J, Blauw GJ, Bax JJ, Westendorp RG. Low blood pressure in the very old, a consequence of imminent heart failure: the Leiden 85-plus Study. J Hum Hypertens 2009; 23: 27-32.
24. Odden MC, Peralta CA, Haan MN, Covinsky KE. Rethinking the association of high blood pressure with mortality in elderly adults: the impact of frailty. Arch Intern Med 2012; 172: 1162-1168.
25. Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006; 144: 884-893.
26. Kai H, Ueno T, Kimura T, Adachi H, Furukawa Y, Kita T et al. CREDO-Kyoto Investigators. Low DBP may not be an independent risk for cardiovascular death in revascularized coronary artery disease patients. J Hypertens 2011; 29: 1889-1896.
27. Davis EM, Appel LJ, Wang X, Greene T, Astor BC, Rahman M et al. African American Study of Kidney Disease and Hypertension Research Collaborative Group. Limitations of analyses based on achieved blood pressure: lessons from the African American study of kidney disease and hypertension trial. Hypertension 2011; 57: 1061-1068.
28. Boutitie F, Gueyffier F, Pocock S, Fagard R, Boissel JP. J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a meta-analysis of individual-patient data. Ann Intern Med 2002; 136: 438-448.
29. Fagard RH, Staessen JA, Thijs L, Celis H, Bulpitt CJ, de Leeuw PW et al. On-treatment diastolic blood pressure and prognosis in systolic hypertension. Arch Intern Med 2007; 167: 1884-1891.
30. Fuchs FD. Blood pressure-lowering drugs: essential therapy for some patients with normal blood pressure. Expert Rev Cardiovasc Ther 2004; 2: 771-775.
31. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.
32. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153.
33. Fox KM. EURopean trial on reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788.
34. PROGRESS Collaborative Group. Randomised trial of a perindopril-based bloodpressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041.
35. The SOLVD investigators. Effect of enalapril on mortality and development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Eng J Med 1992; 327: 685-691.
36. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Eng J Med 1991; 325: 669-677.
37. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown Jr EJ, Cuddy TE et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. The SAVE Investigators. N Eng J Med 1992; 327: 669-677.
38. Thompson AM, Hu T, Eshelbrenner CL, Reynolds K, He J, Bazzano LA. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA 2011; 305: 913-922.
39. Fuchs FD, Fuchs SC, Moreira LB, Gus M, No brega AC, Poli-de-Figueiredo CE et al. Prevention of hypertension in patients with pre-hypertension: protocol for the PREVER-prevention trial. Trials 2011; 12: 65.
40. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Eng J Med 1987; 316: 1429-1435.
41. Reboldi G, Gentile G, Angeli F, Ambrosio G, Mancia G, Verdecchia P. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients. J Hypertens 2011; 29: 1253-1269.
42. McBrien K, Rabi DM, Campbell N, Barnieh L, Clement F, Hemmelgarn BR et al. Intensive and standard blood pressure targets in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 2012; 172: 1296-1303.
43. Smith Jr SC, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA et al. World Heart Federation and the Preventive Cardiovascular Nurses Association. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011; 124: 2458-2473.